Details of the Conference Call:

Wednesday, 15 December 2010 at 16.30 p.m. CEST 15.30 p.m. BST/10.30 a.m. US Time (East Coast)

Dial-in Numbers: Europe: +49 (0)69 2222 2246 (Germany) +44 (0)20 7138 0836 (UK) US: +1 718 354 1172

Pass Code:  5734705

A simultaneous slide presentation for participants dialing in via phone is available at , password: evotec1210. You can also listen to the conference call via audio webcast including presentation slides at .

If you are unable to attend, a recording will be available for 24 hours after the call at the following phone numbers: +49.(0)69.2222 2236 (Germany), +44.(0)20.7111 1244 (UK), +1.347.366 9565 (US). The access code is 5734705#. The on-demand version of the webcast will be available on our website: - Investors/Events/Financial Calendar.


Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialized platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, oncology, inflammation and metabolic diseases. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression and an alliance in the field of diabetes with Andromeda (Teva). For additional information please go to


DeveloGen AG, Gottingen, Germany, is a biopharmaceutical company engaged in the research and development of metabolic diseases. Since September 2010 DeveloGen AG is part of the Evotec group of companies with 99.4% of the outstanding capital acquired by Evotec AG. Under the terms of the acquisition, Evotec AG owes, amongst others, a portion of any upfront, milestone and royalty payments of certain agreements (including the agreement relating to beta cell regeneration assets) entered into by DeveloGen AG as deferred purchase consideration. This agreement also triggers a further share consideration of 1,398,561 shares held in escrow.